DrugPatentWatch Database Preview

Details for Patent: 6,965,027

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,965,027 protect, and when does it expire?

Patent 6,965,027 protects XELJANZ XR and XELJANZ and is included in two NDAs.

This patent has thirty-four patent family members in twenty-nine countries.

Summary for Patent: 6,965,027

Title:	Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1 -yl}-3-oxo-propionitrile citrate
Abstract:	This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-pip eridin-1-yl}-3-oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation.
Inventor(s):	Flanagan; Mark E. (Gales Ferry, CT), Li; Zheng J. (Quaker Hill, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	10/310,078
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,965,027
Patent Claim Types: see list of patent claims	Compound; Process;

Drugs Protected by US Patent 6,965,027

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016		RX	Yes	No				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019		RX	Yes	Yes				Y
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012		RX	Yes	No				Y

International Family Members for US Patent 6,965,027

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	037635
Austria	497962
Australia	2002348857